

Att. Docket No.: 11111/2003G PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Segal, et al.  
Serial No.: 10/667,193  
Filed: September 19, 2003  
Entitled: LECTIN COMPOSITIONS AND  
METHODS FOR MODULATING  
AN IMMUNE RESPONSE TO AN  
ANTIGEN

Examiner: Not Yet Assigned  
Group Art Unit: Not Yet Assigned  
Conf. No.: Not Yet Assigned

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a**

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brenda M. Woods

Name of Person Mailing Paper

*Brenda M. Woods*

Signature of Person Mailing Paper

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Enclosed for filing in the above-identified patent application, please find the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449; and
3. Return Post Card.


The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 11111/2003G. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: October 24, 2003

*Mark J. FitzGerald*

Name: Mark J. FitzGerald  
Registration No.: 45,928  
Palmer & Dodge LLP  
111 Huntington Avenue  
Boston, MA 02199-7613  
Tel: 617-239-0100



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Segal, et al.  
Serial No.: 10/667,193  
Filed: September 19, 2003  
Entitled: LECTIN COMPOSITIONS AND  
METHODS FOR MODULATING  
AN IMMUNE RESPONSE TO AN  
ANTIGEN

Examiner: Not Yet Assigned  
Group Art Unit: Not Yet Assigned  
Conf. No.: Not Yet Assigned

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a**

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brenda M. Woods

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A copy of the cited documents were submitted to the U.S. Patent and Trademark Office in the parent application, U.S. Serial No. 10/645,000. Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Respectfully submitted,

Date: October 24, 2003

Name: Mark J. FitzGerald  
Registration No.: 45,928  
Palmer & Dodge LLP  
111 Huntington Avenue  
Boston, MA 02199-7613  
Tel: 617-239-0100

USPTO Form 1449 U.S. Department of Commerce  
Patent and Trademark Office

## INFORMATION DISCLOSURE STATEMENT

Attorney Docket No.

11111/2003G

Serial No.

10/667,193

Applicant(s): Segal, et al.

Filing Date: September 19, 2003

Group: Not Yet  
Assigned

## U.S. PATENT DOCUMENTS

Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

## FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Publication Date	Country	Class	Subclass	Translation	
						YES	NO

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

1.	Faulkner, L. et al., (2001), "IL-2 linked to a peptide from influenza hemagglutinin enhances T cell activation by affecting the antigen-presentation function of bone marrow-derived dendritic cells", <i>International Immunology</i> , 13(6):713-721
2.	Batova, A. et al., (1999), "The Ch14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity <i>in Vitro</i> ", <i>Clinical Cancer Research</i> , 5:4259-4263.
3.	Frankel, A. et al., (1995), "IL2-Ricin Fusion Toxin Is Selectively Cytotoxic <i>in Vitro</i> to IL2 Receptor-Bearing Tumor Cells", <i>Bioconjugate Chem.</i> , 6:666-672.
4.	Gillies, S.D. et al., (1992), "Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells", <i>Proc. Natl. Acad. Sci. USA</i> , 89:1428-1432.
5.	Barker, E. et al., (1991), "Effect of a Chimeric Anti-Ganglioside G <sub>D2</sub> Antibody on Cell-mediated Lysis of Human Neuroblastoma Cells", <i>Cancer Research</i> , 51:144-149.
6.	Gillies, S.D. et al., (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-Ganglioside GD2 Antibody" <i>Hybridoma</i> , 10(3):347-356.
7.	Deliyannis, G. et al., (2000), "A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge", <i>PNAS</i> , 97(12):6676-6680.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*\*Copies of references not provided at the time of this submission.